Mirae Asset Global Investments Co. Ltd. Raises Position in Zimmer Biomet Holdings, Inc. $ZBH

Mirae Asset Global Investments Co. Ltd. raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,579 shares of the medical equipment provider’s stock after purchasing an additional 6,495 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Zimmer Biomet were worth $3,289,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ZBH. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $204,000. Sivia Capital Partners LLC purchased a new stake in shares of Zimmer Biomet in the second quarter worth approximately $232,000. United Bank raised its stake in shares of Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on ZBH shares. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research note on Friday, January 9th. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Leerink Partners started coverage on Zimmer Biomet in a report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price for the company. Finally, Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $105.95.

Zimmer Biomet Stock Up 0.4%

ZBH stock opened at $93.02 on Thursday. The stock’s fifty day simple moving average is $93.75 and its two-hundred day simple moving average is $93.15. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $108.29. The stock has a market cap of $18.01 billion, a P/E ratio of 26.28, a P/E/G ratio of 1.90 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter in the previous year, the firm earned $2.31 earnings per share. The business’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.39 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is currently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.